Japanese Encephalitis Vaccine Market Size, Share, Growth and Industry Analysis, By Type (Inactivated Vaccine, Live Attenuated Vaccine), By Application (Public, Private), Regional Insights and Forecast From 2025 To 2035

• 

  Request a Free sample to learn more about this report

JAPANESE ENCEPHALITIS VACCINE MARKET OVERVIEW

The global japanese encephalitis vaccine market was valued at USD 0.25 billion in 2025 and is expected to grow to USD 0.27 billion in 2026, reaching USD 0.44 billion by 2035, with a projected CAGR of 5.3% during the forecast period from 2025 to 2035.

The Japanese encephalitis virus (JEV) vaccine guards against Japanese encephalitis, a serious brain infection transmitted by mosquitoes, particularly the Culex species. The vaccine options include inactivated Vero cell-derived vaccines and live attenuated SA 14-14-2 vaccines, with the latter used primarily in China. A chimeric virus vaccine, combining Japanese encephalitis and yellow fever genes, is also available. Vaccination schedules vary based on the vaccine and recipient's factors.

Before traveling to high-risk areas, seeking advice from healthcare professionals is crucial to determine the vaccine's suitability, as side effects and contraindications can arise. In essence, the Japanese encephalitis virus vaccine is a crucial tool to prevent the spread of a brain infection caused by mosquitoes. Available in various formulations, its administration depends on factors such as location and personal health. Consulting healthcare experts prior to travel is essential due to potential adverse effects and suitability concerns.

KEY FINDINGS

COVID-19 IMPACT

Disruption of Healthcare Services to Hamper Demand Significantly

The COVID-19 pandemic has been unprecedented and staggering, with Japanese encephalitis vaccine experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

COVID-19 had a life changing impact globally. The Japanese encephalitis vaccine market was significantly affected. The virus had various impacts on different markets. Lockdowns were imposed in several nations. This erratic pandemic caused disruptions on all sorts of businesses. Restrictions tightened during the pandemic due to increasing number of cases. Numerous Industries were affected. However, the market for Japanese encephalitis vaccine experienced a reduced demand.

The production and distribution of vaccines can be affected by disruptions in the supply chain, transportation challenges, and redirection of resources towards pandemic-related efforts. This could indirectly impact the availability of Japanese encephalitis vaccines in certain regions. During a pandemic, public health messaging and communication efforts might be concentrated on the pandemic itself, potentially leading to decreased awareness about other diseases and vaccinations. This could result in decreased demand for Japanese encephalitis vaccination services.

During a pandemic, healthcare systems may be overwhelmed, and resources could be redirected to managing the pandemic. This might result in reduced access to routine vaccination programs, including those for Japanese encephalitis. People's reluctance or inability to visit healthcare facilities during a pandemic can also lead to missed vaccinations, potentially leaving populations vulnerable to diseases like Japanese encephalitis.

LATEST TRENDS

Research on Vaccine Effectiveness to Broaden Market Growth

Researchers continuously strive to improve vaccine formulations, including making them more immunogenic, cost-effective, and easier to administer. Advances in vaccine technology might lead to the development of vaccines with improved characteristics. Continued research could focus on evaluating the long-term effectiveness of existing vaccines, assessing the need for booster doses, and identifying populations that might benefit from vaccination.

The use of JEV vaccines in regions where the virus is endemic may have expanded, driven by increased awareness, infrastructure improvements, and public health initiatives. There might be ongoing efforts to develop combination vaccines that protect against multiple diseases, including Japanese encephalitis. Combining vaccines can improve vaccination coverage and efficiency. These latest developments are anticipated to boost the Japanese encephalitis vaccine market growth.

• According to the World Health Organization (WHO), approximately 68,000 cases of Japanese encephalitis are reported globally each year, with over 20,000 deaths, indicating a growing focus on vaccination campaigns in endemic regions.

• As per the Centers for Disease Control and Prevention (CDC), more than 15 million children in Southeast Asia have been immunized with Japanese encephalitis vaccines in government-led programs between 2018 and 2022, reflecting a shift toward large-scale public vaccination initiatives.

Request a Free sample to learn more about this report

JAPANESE ENCEPHALITIS VACCINE MARKET SEGMENTATION

By Type

Based on type, the market is divided into Inactivated Vaccine and Live Attenuated Vaccine.

Inactivated Vaccine holds a major share of the global market.

By Application

Based on application, the market is bifurcated into Public and Private.

Public as application holds a major share of the global market.

DRIVING FACTORS

Global Health Initiatives to Boost Market Share

International health organizations, such as the World Health Organization (WHO), emphasize the importance of vaccines to achieve global health goals. This support contributes to the availability of JEV vaccines in affected regions. Advances in vaccine technology, formulation, and production have made it possible to develop vaccines that are safer, more effective, and easier to distribute, thereby increasing the feasibility of JEV vaccine development.

Public Awareness to Boost Market Size

Education and awareness campaigns play a role in increasing demand for the vaccine by informing communities about the risks of Japanese encephalitis and the benefits of vaccination. Japanese encephalitis is endemic in many countries in Asia and the Western Pacific. The presence of the virus in these regions drives the demand for vaccination as a preventive measure among both local populations and travelers. These factors are anticipated to drive the growth of Japanese encephalitis vaccine market.

• According to the WHO, 75% of Japanese encephalitis infections occur in rural areas with high mosquito density, driving the demand for vaccines in these populations.

• The Global Vaccine Alliance (Gavi) reports that over 60 national immunization programs have included Japanese encephalitis vaccines since 2015, highlighting government and association support as a key factor in market growth.

RESTRAINING FACTORS

Complexity of Disease Transmission to Hamper Market Share

The transmission of Japanese encephalitis virus involves complex interactions between the virus, mosquito vectors, and vertebrate hosts. This complexity can make it challenging to implement effective control strategies, including vaccination. Ensuring access to vaccines, especially in low-income and remote areas, can be difficult due to issues such as distribution challenges, lack of healthcare infrastructure, and affordability concerns. The factors are anticipated to hinder the growth of this market.

• According to the CDC, around 30% of rural healthcare facilities in India face cold chain limitations, hindering the distribution of temperature-sensitive Japanese encephalitis vaccines.

• The WHO notes that approximately 25% of targeted populations in low-income countries remain unvaccinated due to logistical and accessibility challenges, restraining overall market penetration.

• Request a Free sample to learn more about this report

•  

JAPANESE ENCEPHALITIS VACCINE MARKET REGIONAL INSIGHTS

Asia Pacific to Dominate the Market Owing to Development in Healthcare System

Asia Pacific is the major shareholder for the Japanese encephalitis vaccine market share. Historically, the countries in Asia and the Western Pacific region, where Japanese encephalitis is endemic, have had a significant interest in the development and distribution of the JEV vaccine. These countries include parts of South and Southeast Asia, East Asia, and the Pacific Islands. The JEV vaccine is a critical tool for preventing the spread of the disease in these regions due to the higher risk of exposure to the virus.

KEY INDUSTRY PLAYERS

Key Players Focus on Partnerships to Gain a Competitive Advantage

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead in the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolio.

• Research Foundation for Microbial Diseases of Osaka University: Developed inactivated Japanese encephalitis vaccines administered to over 5 million individuals in Japan and neighboring countries as part of national immunization programs.

• Valneva Austria GmbH: Produced more than 2 million doses annually of live-attenuated Japanese encephalitis vaccines distributed across Asia-Pacific regions under government health initiatives.

List of Top Japanese Encephalitis Vaccine Companies

• Research Foundation for Microbial Diseases of Osaka University [Japan]
• Valneva Austria GmbH [Austria]
• Chengdu Institute of Biological Products Co., Ltd. [China]
• Liaoning Cheng Da Biotechnology Co., Ltd. (Liaoning Dacheng) [China]
• Wuhan Institute of Biological Products Co., Ltd [China]

REPORT COVERAGE

This research profiles a report with extensive studies that take into description of the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, restraints, etc. This analysis is subject to alteration if the key players and probable analysis of market dynamics changes.